306 related articles for article (PubMed ID: 9083481)
41. Cluster analysis and three-dimensional QSAR studies of HIV-1 integrase inhibitors.
Yuan H; Parrill A
J Mol Graph Model; 2005 Jan; 23(4):317-28. PubMed ID: 15670952
[TBL] [Abstract][Full Text] [Related]
42. Identification of HIV-1 integrase inhibitors via three-dimensional database searching using ASV and HIV-1 integrases as targets.
Chen IJ; Neamati N; Nicklaus MC; Orr A; Anderson L; Barchi JJ; Kelley JA; Pommier Y; MacKerell AD
Bioorg Med Chem; 2000 Oct; 8(10):2385-98. PubMed ID: 11058033
[TBL] [Abstract][Full Text] [Related]
43. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells.
Mekouar K; Mouscadet JF; Desmaële D; Subra F; Leh H; Savouré D; Auclair C; d'Angelo J
J Med Chem; 1998 Jul; 41(15):2846-57. PubMed ID: 9667973
[TBL] [Abstract][Full Text] [Related]
44. Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors.
Langford HM; Williams PD; Homnick CF; Vacca JP; Felock PJ; Stillmock KA; Witmer MV; Hazuda DJ; Gabryelski LJ; Schleif WA
Bioorg Med Chem Lett; 2008 Jan; 18(2):721-5. PubMed ID: 18078751
[TBL] [Abstract][Full Text] [Related]
45. Naphthoxazepine inhibitors of HIV-1 integrase: synthesis and biological evaluation.
Garofalo A; Grande F; Brizzi A; Aiello F; Dayam R; Neamati N
ChemMedChem; 2008 Jun; 3(6):986-90. PubMed ID: 18383063
[TBL] [Abstract][Full Text] [Related]
46. HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
[TBL] [Abstract][Full Text] [Related]
47. Design, synthesis, and anti-integrase activity of catechol-DKA hybrids.
Maurin C; Bailly F; Mbemba G; Mouscadet JF; Cotelle P
Bioorg Med Chem; 2006 May; 14(9):2978-84. PubMed ID: 16412645
[TBL] [Abstract][Full Text] [Related]
48. Conformationally restrained carbazolone-containing alpha,gamma-diketo acids as inhibitors of HIV integrase.
Li X; Vince R
Bioorg Med Chem; 2006 May; 14(9):2942-55. PubMed ID: 16386908
[TBL] [Abstract][Full Text] [Related]
49. Synthesis, antiviral, and anti-HIV-1 integrase activities of 3-aroyl-1,1-dioxo-1,4,2-benzodithiazines.
Brzozowski Z; Saczewski F; Sanchez T; Kuo CL; Gdaniec M; Neamati N
Bioorg Med Chem; 2004 Jul; 12(13):3663-72. PubMed ID: 15186851
[TBL] [Abstract][Full Text] [Related]
50. QSAR study of substituted 1,3,4-oxadiazole naphthyridines as HIV-1 integrase inhibitors.
Ravichandran V; Shalini S; Sundram K; Sokkalingam AD
Eur J Med Chem; 2010 Jul; 45(7):2791-7. PubMed ID: 20347187
[TBL] [Abstract][Full Text] [Related]
51. Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance.
Loizidou EZ; Zeinalipour-Yazdi CD; Christofides T; Kostrikis LG
Bioorg Med Chem; 2009 Jul; 17(13):4806-18. PubMed ID: 19450984
[TBL] [Abstract][Full Text] [Related]
52. 3D-QSAR studies of quinoline ring derivatives as HIV-1 integrase inhibitors.
Sun XH; Guan JQ; Tan JJ; Liu C; Wang CX
SAR QSAR Environ Res; 2012 Oct; 23(7-8):683-703. PubMed ID: 22991976
[TBL] [Abstract][Full Text] [Related]
53. Treating chemical diversity in QSAR analysis: modeling diverse HIV-1 integrase inhibitors using 4D fingerprints.
Iyer M; Hopfinger AJ
J Chem Inf Model; 2007; 47(5):1945-60. PubMed ID: 17661457
[TBL] [Abstract][Full Text] [Related]
54. Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase.
Verschueren WG; Dierynck I; Amssoms KI; Hu L; Boonants PM; Pille GM; Daeyaert FF; Hertogs K; Surleraux DL; Wigerinck PB
J Med Chem; 2005 Mar; 48(6):1930-40. PubMed ID: 15771437
[TBL] [Abstract][Full Text] [Related]
55. X-ray and molecular modelling in fragment-based design of three small quinoline scaffolds for HIV integrase inhibitors.
Majerz-Maniecka K; Musiol R; Skórska-Stania A; Tabak D; Mazur P; Oleksyn BJ; Polanski J
Bioorg Med Chem; 2011 Mar; 19(5):1606-12. PubMed ID: 21316973
[TBL] [Abstract][Full Text] [Related]
56. Chemistry and structure-activity relationship of HIV-1 integrase inhibitor integracide B and related natural products.
Singh SB; Ondeyka JG; Schleif WA; Felock P; Hazuda DJ
J Nat Prod; 2003 Oct; 66(10):1338-44. PubMed ID: 14575434
[TBL] [Abstract][Full Text] [Related]
57. HIV-1 integrase inhibitors: 2005-2006 update.
Dayam R; Gundla R; Al-Mawsawi LQ; Neamati N
Med Res Rev; 2008 Jan; 28(1):118-54. PubMed ID: 17979144
[TBL] [Abstract][Full Text] [Related]
58. Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine.
Wang Z; Vince R
Bioorg Med Chem; 2008 Apr; 16(7):3587-95. PubMed ID: 18314335
[TBL] [Abstract][Full Text] [Related]
59. Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore.
Hong H; Neamati N; Winslow HE; Christensen JL; Orr A; Pommier Y; Milne GW
Antivir Chem Chemother; 1998 Nov; 9(6):461-72. PubMed ID: 9865384
[TBL] [Abstract][Full Text] [Related]
60. Integrase inhibitors for the treatment of HIV infection.
Pace P; Rowley M
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
